스냅차트

Will Covid-19 Hurt or Help Healthcare Companies? It Depends

Prospects have improved for alternative sites of care, telemedicine, modernization of clinical trials, and healthcare provider consolidation.

스냅차트

Will Covid-19 Hurt or Help Healthcare Companies? It Depends
en

The pandemic’s effects vary greatly among different healthcare sectors. Covid-19 forced delays or cessations of both preventive and elective procedures, and disrupted supply chains for critical equipment and medicines. But it also has accelerated opportunities for alternative sites of care, telemedicine, modernization of clinical trials, and healthcare provider consolidation.

Bain & Company built demand scenarios for periods during the pandemic, immediately after it wanes, and then the longer-term outlook. The scenarios, while simplified, can help executives and investors understand how various segments will be affected. Testing equipment and online pharmacy use, for instance, could likely reset at a permanently higher level of demand once the pandemic abates. Conversely, demand for hospital-based elective procedures, which were already shifting to outpatient settings, could move permanently lower. Overall, though, the healthcare industry remains highly attractive for private equity investors that have capital to deploy.

From Bain's Healthcare Private Equity and M&A Report

The Covid-19 Paradox

Three demand scenarios can inform investment strategies.

태그

베인에 궁금하신 점이 있으신가요?

베인은 글로벌 리더들이 중요한 이슈를 해결하고 기회를 놓치지 않도록 지원합니다. 고객사와 협력하여 지속되는 변화와 성과를 창출합니다.